@ShahidNShah
Pfizer, Merck launch large new trials of oral COVID-19 drugs
- Pfizer and Merck & Co. each launched pivotal clinical studies of new experimental oral COVID-19 drugs, building on previous work to provide outpatient alternatives for patients.
- Merck is studying whether its medicine, molnupiravir, can prevent COVID-19 in adults who live with a symptomatic patient with a confirmed coronavirus infection. The trial will include about 1,300 patients who will take molnupiravir or a placebo every 12 hours for five days.
- Pfizer said the first of about 1,140 patients has received a dose of its therapy in a trial to treat symptomatic patients who have not been hospitalized and aren’t at high risk of severe illness. The dosing of the Pfizer treatment — a combination of an older medicine and an experimental drug called PF-07321332 — is also every 12 hours for five days and measured against a placebo.
Continue reading at healthcaredive.com
Make faster decisions with community advice
- Wearable fitness company WHOOP acquires sports tech startup PUSH
- 10 Reasons the Healthcare Industry is Still Not Innovating in 2021
- How data use will revolutionise women’s healthcare
- Solv Raises $45M to Expand Same-Day Appts & Virtual Care Options Nationwide
- Artificial Intelligence Will Redesign Healthcare
Next Article
-
Wearable fitness company WHOOP acquires sports tech startup PUSH
Digital health and fitness company WHOOP announced the acquisition of sports technology startup PUSH Thursday in an undisclosed cash and stock transaction. The news comes days after WHOOP said it had …
Posted Sep 6, 2021 Mergers & Acquisitions